CAR-T cell therapy as first treatment for high-risk large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the CAR-T cell therapy axicabtagene ciloleucel (a type of immunotherapy made from your own immune cells) can be effective as a first treatment for people with aggressive large B-cell lymphoma that hasn't responded well after two rounds of chemoimmunotherapy. It's designed for patients with high-risk features who might need a stronger approach early on.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma confirmed by biopsy, including common subtypes like DLBCL or high-grade B-cell lymphoma.
- You have a high-risk IPI score of 2 to 5 at diagnosis.
- After two cycles of standard chemoimmunotherapy, your PET scan shows a score of 4 or 5 (indicating remaining active disease) or your ctDNA levels have not dropped enough.
- You are 18 years or older.
- Your overall health status is good (ECOG score 0-2) and your organs are working well enough (kidney, liver, heart, lungs).
- You have at least one measurable tumor on imaging.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This trial tests whether a type of immunotherapy called axicabtagene ciloleucel (a CAR T-cell therapy) can improve outcomes when given right after initial treatment for high-risk large B-cell lymphoma. It is for people who have not yet started treatment.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
This trial tests whether a second infusion of a CAR-T cell therapy called Axi-cel, given early based on a blood test (ctDNA), can help people with relapsed or hard-to-treat large B-cell lymphoma. If you had a partial response or your ctDNA stayed positive after the first dose, you may be eligible.
This early-stage trial tests an automated version of axicabtagene ciloleucel (a CAR-T cell therapy) for large B-cell lymphoma that has come back or stopped responding to initial chemotherapy. CAR-T therapy uses your own immune cells, modified in a lab to fight cancer cells.
Hear when a new CAR-T Cell Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.